For in vitro diagnostic use. Cytoplasm Others BRAF V600E VE1 US Export VENTANA IVD Colorectal Cells VENTANA® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody RTD001191 For use with VENTANA MMR IHC Panel, CE-IVD Mouse VE1 08 033 706 001 8 033 706 001 08033706001 8033706001 08033706001 BRAF V600E (VE1) MM PAB-US Export VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody 07613336119396 Reagents, kits 760-5095 50 tests Not Available true VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody (VENTANA anti-BRAF V600E (VE1) antibody) is intended for the qualitative detection of BRAF V600E protein in formalin-fixed, paraffin-embedded tissue sections. VENTANA anti-BRAF V600E (VE1) antibody is ready to use on BenchMark IHC/ISH instruments with the OptiView DAB IHC Detection Kit and ancillary reagents. VENTANA anti-BRAF V600E (VE1) antibody is part of the VENTANA MMR IHC Panel which includes VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody, VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody and VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody. The VENTANA MMR IHC Panel is indicated for the detection of mismatch repair protein deficiency as a test for the identification of individuals at risk for Lynch syndrome in patients diagnosed with colorectal cancer (CRC), and, with BRAF V600E status, as an aid to differentiate between sporadic and probable Lynch syndrome CRC in the absence of MLH1 protein expression. These products should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls. Intended for in vitro diagnostic (IVD) use. en The VENTANA anti-BRAF V600E (VE1) antibody is a mouse monoclonal antibody (clone VE1) produced against a synthetic peptide representing the BRAF mutated amino acid sequence from amino acid 596 to 606 (GLATEKSRWSG). This mutation-specific antibody Figure 1. VENTANA anti-BRAF V600E (VE1) antibody staining of neoplastic cells in colon cancer tissue. 2023-08-16 2 / 10 1015767EN Rev F FT0700-410u exhibits a cytoplasmic staining pattern. This antibody differentiates the V600E mutation in the BRAF protein from the wild type BRAF protein and other mutated BRAF proteins.33,34 In the context of mismatch repair (MMR) IHC testing for potential Lynch syndrome, the identification of the BRAF V600E mutation in MLH1 loss cases is indicative of sporadic colorectal cancer (CRC).32VENTANA anti-BRAF V600E (VE1) antibody binds specifically to the BRAF V600E mutant protein in formalin-fixed, paraffin-embedded (FFPE) tissue sections. The antibody can be localized using a haptenated secondary antibody followed by a multimer anti-hapten-HRP conjugate (OptiView DAB IHC Detection Kit, Cat. No. 760-700 / 06396500001). The specific antibody-enzyme complex is then visualized with a precipitating enzyme reaction product. Each step is incubated for a precise time and temperature. At the end of each incubation step, the instrument washes the sections to stop the reaction and to remove unbound material that would hinder the desired reaction in subsequent steps. It also applies ULTRA LCS (Predilute) (Cat. No. 650-210 / 05424534001) or LCS (Predilute) (Cat. No. 650-010 / 05264839001), which minimizes evaporation of the aqueous reagents from the specimen slide. en

User Profile

Select your user profile

VENTANA^® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

Technical Documents

Access important product documentation including relevant certificates and other resources.